Features | Partner Sites | Information | LinkXpress
Sign In
ElsMed
Samsung
Ampronix

Simplified Alzheimer’s Disease Diagnosis Using PET Imaging and More Effective Criteria

By Medimaging International staff writers
Posted on 24 Jul 2014
According to French investigators, over one-third of patients receive an incorrect diagnosis of Alzheimer’s disease (AD). To reduce the number of errors, the diagnostic criteria available must be the most reliable possible, especially at the very early stages of the disease. For the past 10 years, an international team of neurologists has been working towards this objective. The researchers recently introduced new diagnostic criteria, in particular, biomarkers. These are authentic signatures of the disease, and are present from the first symptoms (prodromal stage).

In the June 2014 issue of the Lancet Neurology journal, Dr. Bruno Dubois, from the National de la Santé et de la Recherche Médicale (Inserm; Paris, France) and Pierre and Marie Curie University (Paris, France) /AP-HP Joint Research Unit 975) and colleagues have developed a simplified diagnosis based on the most specific criteria of the disease, which should have a major impact in clinical practice.

AD is the most common (70%) form of dementia. The real challenge of a definitive diagnosis is to know how to differentiate this disease from other types of dementia, and establish the diagnosis as effectively and as early as possible.

In 2005, an international group of neurologists, coordinated by Inserm’s Dr. Bruno Dubois, came together to redefine the diagnostic criteria established in 1984. Up to then, it had been necessary to await the death of a patient in order to establish a diagnosis of AD with certainty by examining the lesions in his/her brain. And in the living, only a probability of disease could be inferred, and only at a late stage, based on a certain threshold of severity of dementia.

In 2007, the international team broke these hypotheses apart. The researchers introduced new diagnostic criteria, particularly biomarkers. These are authentic signatures of the disease, and are present from the initial symptoms (prodromal stage). The publication of these findings initiated a transformation. Researchers then observed that with these new criteria, “36% of their patients included in a therapeutic trial based on previous clinical criteria did not have Alzheimer’s disease,” reported Prof. Dubois. However, although this analysis involved only a subgroup of patients, the implications are serious. Patients did not receive the correct treatment and/or care. Moreover, flawed patient selection might have had an impact on the lack of efficacy observed for the new treatment.

Since 2007, many studies have been published. The international group decided to analyze this literature to make the diagnostic algorithm for AD simpler and more reliable. “We have reached the end of the road; we have arrived at the essence, something refined, resulting from an international consensus,” indicated Prof. Dubois. The diagnosis of Alzheimer’s disease will henceforth rely on “just a couple of clinical-biological criteria for all stages of the disease.”

Most of the time, the diagnosis of AD is based primarily on a suggestive clinical picture. It is subsequently confirmed or rejected using a biomarker. As regards the clinical picture, there are three scenarios: (1) typical cases (80%–85% of all cases): impairment of episodic long-term memory (known as amnestic syndrome of the hippocampal type and corresponding to difficulty remembering a list a words, even with clues, for example); (2) atypical cases (15%–20% of cases): atrophy of the posterior part of the cerebral cortex or logopenic aphasia (impairment of verbal memory where the patient inverts the syllables of a word when repeating it, for example), or frontal brain damage, which results in behavioral problems; (3) preclinical states: asymptomatic at-risk (patients without symptoms, but who are fortuitously discovered to have positive biomarkers during scientific studies), and presymptomatic (with a genetic mutation).

One of the following two biomarkers is required: (1) in the cerebrospinal fluid (obtained by lumbar puncture) to ascertain abnormal levels of brain proteins (reduced beta amyloid protein and increased tau protein); (2) and in the brain by positron emission tomography (PET) neuroimaging to determine the elevated retention of amyloid tracer.

This simpler and more effective algorithm is important, mainly for research (therapeutic trials, characterization of the disease, monitoring of patient cohorts), according to the investigators. Outside of research, the use of biomarkers, which is expensive and/or invasive, currently remains limited to young patients or difficult or complex cases in specialty centers.

Related Links:
National de la Santé et de la Recherche Médicale
Pierre and Marie Curie University




ARAB HEALTH
Supersonic Imagine
PHS Technologies

Channels

Radiography

view channel

Low-Dose CT Offers Cost-Effective Lung Screening

A new statistical analysis of from a US lung screening trial concluded that performing low-dose computed tomography (CT) screening can be cost-effective compared to doing no screening for lung cancer in aging smokers. “This provides evidence, given the assumptions we used, that it is cost-effective,” said Ilana Gareen,... Read more

MRI

view channel
Image: Differences in the brains of autistic and control subjects using MRI (Photo courtesy of Center of Cognitive Brain Imaging, Carnegie Mellon University).

MRI Shows Brain Anatomy Differences Between Autistic and Typically Developing Individuals to Be Mostly Indistinguishable

In the largest magnetic resonance imaging (MRI) study of patients with autism to date, Israeli and American researchers have shown that the brain anatomy in MRI scans of autistic individuals older than... Read more

General/Advanced Imaging

view channel

Photoacoustic Imaging Optimizes Visualization of Cancerous Tissues Using Time Reversal Technology

Unique time-reversal technology is being used to better focus light in tissue, such as muscles and organs. Current high-resolution optical imaging technology allows researchers to see about 1-mm-deep into the body. In an effort to enhance this imaging technology, the investigators are employing photoacoustic imaging, which... Read more

Imaging IT

view channel
Image: The ResolutionMD enterprise image viewer provides rapid access to diagnostic images from any mobile or web device (Photo courtesy of Calgary Scientific).

Enterprise Image Viewer Provides Rapid Access to Images from Any Mobile or Web Device

New enhancements to an enterprise image viewer enable new ways of working for physicians, even when they are not working inside a caregiving facility. The solution provides rapid access to diagnostic images... Read more

Industry News

view channel
Image: Blackford Analysis accelerates image comparison (Photo courtesy of Blackford Analysis).

Partnership to Integrate Image Workflow Server into Image Viewer

Intelerad Medical Systems (Montreal, Canada), a developer of medical imaging picture archiving and communication systems (PACS), radiology information systems (RIS), and workflow solutions, reported that... Read more
 

Events

01 Dec 2014 - 05 Dec 2014
11 Jan 2015 - 14 Jan 2015
Copyright © 2000-2014 Globetech Media. All rights reserved.